Technical Analysis for CADL - Candel Therapeutics, Inc.

Grade Last Price % Change Price Change
F 5.28 0.00% 0.00
CADL closed unchanged on Friday, November 1, 2024, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish 0.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 19 hours ago
Possible Inside Day about 19 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Down 2 % about 23 hours ago
Lower Bollinger Band Support about 23 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Candel Therapeutics, Inc. Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Drugs Immunotherapy Surgery Tumor Cancer Immunotherapy Chemotherapy Radiation Pancreatic Cancer Metastases

Is CADL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.3
52 Week Low 0.75
Average Volume 263,161
200-Day Moving Average 5.44
50-Day Moving Average 6.35
20-Day Moving Average 5.80
10-Day Moving Average 5.53
Average True Range 0.38
RSI (14) 31.51
ADX 15.3
+DI 13.21
-DI 17.77
Chandelier Exit (Long, 3 ATRs) 5.90
Chandelier Exit (Short, 3 ATRs) 6.26
Upper Bollinger Bands 6.43
Lower Bollinger Band 5.17
Percent B (%b) 0.09
BandWidth 21.85
MACD Line -0.31
MACD Signal Line -0.26
MACD Histogram -0.0486
Fundamentals Value
Market Cap 152.7 Million
Num Shares 28.9 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -4.80
Price-to-Sales 1334.04
Price-to-Book 1.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.51
Resistance 3 (R3) 5.50 5.40 5.47
Resistance 2 (R2) 5.40 5.34 5.41 5.46
Resistance 1 (R1) 5.34 5.30 5.37 5.36 5.45
Pivot Point 5.25 5.25 5.26 5.25 5.25
Support 1 (S1) 5.19 5.19 5.22 5.20 5.11
Support 2 (S2) 5.09 5.15 5.10 5.10
Support 3 (S3) 5.03 5.09 5.09
Support 4 (S4) 5.05